ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0679

Comparing Raynaud’s Phenomenon Measurement Tools: Results of the Optimizing Raynaud Phenomenon Outcome Measures in Systemic Sclerosis (ROSS) Study

Rachel Wallwork1, Haomin Hu2, Ami Shah3, Laura Hummers4, John Pauling5, Victoria Flower6, Bambang Parmanto2, Andi Saptono2 and Robyn Domsic7, 1Johns Hopkins University, Towson, MD, 2University of Pittsburgh, Pittsburgh, PA, 3Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, 4Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, 5North Bristol NHS Trust, Bristol, United Kingdom, 6Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 7Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA

Meeting: ACR Convergence 2024

Keywords: Outcome measures, Patient reported outcomes, Raynaud's phenomenon, Scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Systemic Sclerosis & Related Disorders – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Raynaud’s phenomenon (RP) is the most common symptom in systemic sclerosis (SSc) and can lead to significant morbidity, including digital ulcers and/or gangrene.  Despite biologic plausibility and clinical experience supporting the efficacy of several drug classes, clinical trials have demonstrated mixed results. Thus, there are no FDA-approved medications to treat RP.  A proposed reason for the inconsistent trial results is the lack of an accurate RP outcome measure. In this study, we compare the traditional paper diary method for recording frequency and duration of RP attacks to a new smartphone application (Figure 1).

Methods: We conducted a multi-center, prospective, cross-over study of patients with stable SSc-RP. Participants were randomized to record their RP attack frequency and duration via paper diary or smartphone for one week and then crossed over to the other recording method the subsequent week. Participants filled out a questionnaire about their experience.  We compared patient preferences and experiences, and RP attack frequency and duration by recording method. Comparisons were made by paired t-test, McNemar’s test and Wilcoxon rank sum test as appropriate.

Results: Twenty-four patients with stable SSc-RP completed the study (Table 1). Most participants were female (21 [88%]) with a mean (SD) age of 61.6 (8.9) years and RP duration of 19.8 (13.5) years. Participants felt that both the paper (83%) and smartphone (96%) diary were easy to use (p=0.38).  Significantly more reported “liking” the smartphone application than the paper diary (92% vs. 58%, p=0.04). Additionally, 18 (75%) participants preferred the smartphone application, while only 5 (21%) preferred the paper diary and 1 (4%) had no preference (p=0.01). 

Importantly, participants more frequently recorded the RP attack in real-time with the smartphone than the paper diary (71% vs. 38%, p=0.06), and participants less frequently recorded RP attacks at the end of the day (based on memory) with the smartphone (38%) vs paper (71%, p=0.08).  Participants recorded significantly more attacks with the paper diary than with the smartphone application (mean [SD] attacks/day 2.50 [2.10] vs. 1.45 [1.60], respectively, p=0.002); Table 2). Notably, the average attack length was not significantly different between recording methods (paper diary: 21.35 [21.59] minutes/attack vs. smartphone: 24.61 [48.49] minutes/attack; p=0.73). Participants were more likely to miss an attack because the paper diary was not with them compared with the smartphone application (p=0.02).

Conclusion: This study indicates that patients prefer using a smartphone application compared with a paper diary to record RP attacks. Additionally, since 33% more patients recorded their RP attacks in real-time with the smartphone application, this method is likely more accurate as it is less susceptible to recall bias.  The significantly higher number of attacks recorded in the paper diary compared to the smartphone application suggests patients may overestimate their RP attack frequency when completing the form at the end of the day.  Future clinical trials should consider using a smartphone-based application to capture RP attacks.

Supporting image 1

Figure 1. Raynaud smartphone application

Supporting image 2

Table 1. Patient Characteristics (N=24)

Supporting image 3

Table 2. Comparison of paper diary and smartphone application as Raynaud’s reporting methods (N=24)


Disclosures: R. Wallwork: None; H. Hu: None; A. Shah: Arena Pharmaceuticals, 5, Kadmon, 5, Medpace LLC, 5; L. Hummers: AbbVie/Abbott, 2, AstraZeneca, 5, Biotest, 1, 2, Boehringer-Ingelheim, 2, 5, Cumberland, 5, GlaxoSmithKlein(GSK), 5, Kadmon, 5, Medpace, 5, Merck/MSD, 5, Mitsubishi Tanabe, 5, prometheus, 5; J. Pauling: AstraZeneca, 1, 2, Boehringer-Ingelheim, 2, 6, CSL Vifor, 12, Educational meeting attendance, IsoMab, 2, Janssen, 2, 6, Permeatus, 2, Sojournix Pharma, 2; V. Flower: None; B. Parmanto: None; A. Saptono: None; R. Domsic: AstraZeneca, 2.

To cite this abstract in AMA style:

Wallwork R, Hu H, Shah A, Hummers L, Pauling J, Flower V, Parmanto B, Saptono A, Domsic R. Comparing Raynaud’s Phenomenon Measurement Tools: Results of the Optimizing Raynaud Phenomenon Outcome Measures in Systemic Sclerosis (ROSS) Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/comparing-raynauds-phenomenon-measurement-tools-results-of-the-optimizing-raynaud-phenomenon-outcome-measures-in-systemic-sclerosis-ross-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparing-raynauds-phenomenon-measurement-tools-results-of-the-optimizing-raynaud-phenomenon-outcome-measures-in-systemic-sclerosis-ross-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology